IntelliCell BioSciences Becomes Fully Reporting

NEW YORK, NY--(Marketwired - October 07, 2013) - IntelliCell Biosciences, Inc. (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous vascular cells (SVC’s) derived from the blood vessels, announced today that it has filed its 10Q quarterly report and is now in full compliance with SEC regulations as a fully reporting public company as reflected under the Securities Exchange Act of 1934. Due to the reestablishment of compliance, the company’s shares are now trading on the OTCQB exchange.

Dr. Steven Victor, the Chairman and CEO of IntelliCell Biosciences, commented, “We are pleased to announce we have filed our last remaining outstanding quarterly report, which now makes us a fully reporting company. We are gaining tremendous momentum with our stem cell product lines, and believe that now is the ideal time to position the company to attract new investors. Going forward, we will focus our efforts in developing our stem cell technology at our facilities in New York, and other healthcare institutions across the US and internationally.”

As of October 02, 2013, there were approximately 140,839,646 common shares issued and outstanding. To review our public filings with the SEC please visit www.sec.gov

About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC’s) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.www.intellicellbiosciences.com

Forward-Looking Statements
Certain statements set forth in this press release constitute “forward-looking statements.” Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words “estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,” “expect,” “believe,” “will likely,” “will reach,” “will change,” “will soon,” “should,” “could,” “would,” “may,” “can” or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company’s actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company’s ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company’s limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company’s business and financial results is included in the Company’s filings, available via the United States Securities and Exchange Commission.